Growth Metrics

Axsome Therapeutics (AXSM) Liabilities and Shareholders Equity (2021 - 2026)

Axsome Therapeutics' Liabilities and Shareholders Equity history spans 6 years, with the latest figure at $713.6 million for Q1 2026.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 19.6% to $713.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $2.7 billion, a 19.24% increase, with the full-year FY2025 number at $689.8 million, up 21.34% from a year prior.
  • Liabilities and Shareholders Equity hit $713.6 million in Q1 2026 for Axsome Therapeutics, up from $689.8 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for AXSM hit a ceiling of $713.6 million in Q1 2026 and a floor of $88.6 million in Q1 2022.
  • Historically, Liabilities and Shareholders Equity has averaged $509.6 million across 5 years, with a median of $568.5 million in 2024.
  • Biggest five-year swings in Liabilities and Shareholders Equity: skyrocketed 339.45% in 2023 and later fell 10.37% in 2024.
  • Tracing AXSM's Liabilities and Shareholders Equity over 5 years: stood at $331.5 million in 2022, then soared by 77.46% to $588.2 million in 2023, then decreased by 3.36% to $568.5 million in 2024, then grew by 21.34% to $689.8 million in 2025, then increased by 3.45% to $713.6 million in 2026.
  • Business Quant data shows Liabilities and Shareholders Equity for AXSM at $713.6 million in Q1 2026, $689.8 million in Q4 2025, and $669.2 million in Q3 2025.